Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Total 13F shares
-
12,136,541
-
Share change
-
+1,514,611
-
Total reported value
-
$47,926,746
-
Price per share
-
$3.95
-
Number of holders
-
47
-
Value change
-
+$6,035,294
-
Number of buys
-
16
-
Number of sells
-
13
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q3 2023
As of 30 Sep 2023,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,136,541 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Avidity Partners Management LP, Artal Group S.A., CHI Advisors LLC, Flagship Pioneering Inc., Samsara BioCapital, LLC, Deep Track Capital, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, and DAFNA Capital Management LLC.
This page lists
47
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.